Plus Therapeutics

02/18/2026

February is . In 2025, over 2 million people were diagnosed with cancer and over 600 thousand died from this devastating disease in the US, despite 40% of these cases being preventable (American Association for Cancer Research (AACR)).

CNSide Diagnostics’ Cerebrospinal Fluid Assay Platform was developed for patients with suspected to support the prompt diagnosis and treatment initiation essential to improving the chances of controlling the disease, managing symptoms, and extending survival.

Learn more about our game changing diagnostic technology: cnside-dx.com

02/11/2026

On International Day of Women and Girls in Science, we wanted to highlight a few members of our exceptional CNSide Diagnostics' on-site lab team!

We’re proud to celebrate the game changing innovative women working across the and teams, as well as across the world, who drive forward our efforts to develop lasting solutions for treating rare and difficult-to-treat cancers for patients.

02/11/2026

CNSide Diagnostics Medical Science Liason, Kelly Kreitzburg Ondrasek, PhD, attended the National Comprehensive Cancer Network's event to share the latest updates and coming milestones of the Cerebrospinal Fluid Assay Platform for patients with suspected .

Thank you to all who stopped by our booth! Learn more here: cnside-dx.com

02/09/2026

Pharma's Almanac recently asked several key biopharma leaders: What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?

' President and CEO, Marc Hedrick, MD, believes that the future of biopharma will be driven by advances in precision medicine, particularly within the metastatic CNS cancers such as , as researchers gain a deeper understanding of metastatic cancer biology.

Check out Dr. Hedrick’s full response here: https://bit.ly/4tpHEdz

CNSide Diagnostics

02/03/2026

As we move into 2026, and CNSide Diagnostics are progressing forward with a shared focus on improving care for CNS cancer patients.

Coming off a strong 2025, our team is looking forward to advancing each of these key milestones, which reflect a continued commitment to innovation, access, and impact in the fight against cancer.

Learn more via our newest corporate presentation: bit.ly/3ZfdJqN

01/29/2026

In a recent interview with Karen Jagoda of Empowered Patient Radio, Marc Hedrick, President & CEO of , provides a comprehensive overview of 's work to advance diagnostics, targeted , and data for central nervous system (CNS) cancers, with the goal of improving patient outcomes and addressing significant unmet needs in neuro-oncology.

Listen to their discussion here: https://bit.ly/3NE4uxY

CNSide Diagnostics

Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc.,  has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic....

01/26/2026

CNSide Diagnostics has several open positions based out of our new Houston, TX facility.

View all our open positions here: https://hubs.la/Q040lXzP0
Learn more about CNSide: https://hubs.la/Q040lTxM0

01/22/2026

today provides a business update and highlights clinical progress and US commercialization.

Read the full press release here: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-provides-business-update-reyobiqtm-clinical

Learn more in ’s corporate presentation: https://ir.plustherapeutics.com/static-files/474e8e06-2985-41d7-9c71-1592efd35483

CNSide Diagnostics

01/20/2026

and CNSide Diagnostics are looking forward to participating in the Inaugural Brain & Spine Metastases Conference this Thursday in Miami, Florida.

Our team is eager to engage with leading clinicians and researchers, hear the latest updates and practical strategies in the management of brain metastases, and discuss how 's innovative diagnostic capabilities are working to address critical unmet needs in this field.

Learn more about the event: https://bit.ly/4b9t0AD

Learn more about CNSide here: cnside-dx.com

01/16/2026

At , President & CEO Marc Hedrick, MD, shared forward‑looking insights with Labiotech.eu on how 2026 may mark a turning point for the field, driven by the rise of ultra‑precise, minimally invasive platforms poised to redefine cancer treatment.

Read more: https://bit.ly/4jG27Gy

This year, JPM 2026 took place again in San Francisco. Let’s look at predictions and trends forecast for 2026, according to attendees at JPM.

01/12/2026

New Resource for Cancer Patients and Physicians: The Leptomeningeal Metastases Clinical Education Poster

and CNSide Diagnostics are proud to collaborate with the Leptomeningeal Cancer Foundation to help create a new educational resource designed for people who may be facing (LM) as well as their caregivers and care teams.

This poster explains:
- What LM is and how it develops
- Common symptoms to watch for
- How LM is diagnosed
- Why advances in diagnostics and targeted therapies offer hope

By working together with patient advocates, our goal is to ensure accurate, accessible information reaches those who need it when it matters most.

Download this resource here: bit.ly/4qO54qW

01/08/2026

announces the completion of a Type B meeting with the U.S. Food and Drug Administration on next steps on pivotal strategy for (LM). The meeting resulted in constructive discussion with the regarding key elements of the potential pivotal study design for REYOBIQ in LM.

intends to incorporate this feedback in the current dose optimization trial and seek alignment with the FDA on a revised protocol, likely later this year. The company’s goal is to be ready for a potential pivotal trial following completion of the current dose optimization trial and, ultimately, work towards the potential approval of REYOBIQ for patients affected by LM.

Full press release here: bit.ly/4qc4WBL

More about REYOBIQ™: plustherapeutics.com/reyobiq